PLX icon

Protalix BioTherapeutics
PLX

Overview Fund Activity

29 hedge funds and large institutions have $12.5M invested in Protalix BioTherapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
4
Closed
3
Calls
–
Puts
$12K
Net Calls
-$12K
Net Calls Change
+$23K

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$103K
2
HIIFS
2
Harel Insurance Investments & Financial Services
Israel
$23K
3
GC
3
Guggenheim Capital
Illinois
$23K
4
WS
4
Wedbush Securities
California
$17K
5
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$6K

Top Sellers

1
BC
1
Broadfin Capital
New York
$0
2
Barclays
2
Barclays
United Kingdom
$290K
3
Citadel Advisors
3
Citadel Advisors
Florida
$0
4
SIM
4
Spark Investment Management
New York
$34K
5
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$1K
Name Holding Trade Value Shares
Change 		Shares
Change %
Bank of America
26
Bank of America
North Carolina
$1K – – –
BC
27
Broadfin Capital
New York
– -$1.3M -202,527 Closed
Citadel Advisors
28
Citadel Advisors
Florida
– -$7K -1,068 Closed
1
2